Christopher A. Toth - Jun 1, 2023 Form 4 Insider Report for BAXTER INTERNATIONAL INC (BAX)

Role: EVP, Group Pres, Kidney Care
Signature: /s/ Matthew Rice, as attorney in-fact for Christopher A. Toth
Stock symbol: BAX
Transactions as of: Jun 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/5/2023, 04:03 PM
Next filing: Mar 8, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BAX	Common Stock, $1 par value	Award	$0	+106K		$0.00	106K	Jun 1, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Mr. Toth received a grant of restricted stock units (RSUs)in connection with his appointment as EVP and Group President, Kidney Care. The RSUs are scheduled to vest in three equal annual installments beginning on June 3, 2024, the first anniversary of the grant date, subject to the terms and conditions set forth in the Baxter International Inc. 2021 Equity Plan. However, this award grant will vest in full if (i) by December 31, 2024, the proposed separation of the Kidney Care business (comprised of the Renal Care and Acute Therapies businesses) as a separately traded company (the "Business Transaction") does not occur; or (ii) in connection with the consummation of the Business Transaction, Mr. Toth is not appointed as Chief Executive Officer of the new company, Kidney Co.

Content

Mr. Toth received a grant of restricted stock units (RSUs)in connection with his appointment as EVP and Group President, Kidney Care. The RSUs are scheduled to vest in three equal annual installments beginning on June 3, 2024, the first anniversary of the grant date, subject to the terms and conditions set forth in the Baxter International Inc. 2021 Equity Plan. However, this award grant will vest in full if (i) by December 31, 2024, the proposed separation of the Kidney Care business (comprised of the Renal Care and Acute Therapies businesses) as a separately traded company (the "Business Transaction") does not occur; or (ii) in connection with the consummation of the Business Transaction, Mr. Toth is not appointed as Chief Executive Officer of the new company, Kidney Co.